CO4920232A1 - Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin - Google Patents

Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin

Info

Publication number
CO4920232A1
CO4920232A1 CO97075531A CO97075531A CO4920232A1 CO 4920232 A1 CO4920232 A1 CO 4920232A1 CO 97075531 A CO97075531 A CO 97075531A CO 97075531 A CO97075531 A CO 97075531A CO 4920232 A1 CO4920232 A1 CO 4920232A1
Authority
CO
Colombia
Prior art keywords
dibenzo
cyclloheptane
receptor antagonist
antagonist activity
acetic acids
Prior art date
Application number
CO97075531A
Other languages
English (en)
Inventor
William H Miller
William E Bondinell
Ku Thomas Wen Fu
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CO4920232A1 publication Critical patent/CO4920232A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Abstract

Un compuesto que es: Acido (±)-10,11-dihidro-3-[3-(4-amino-2-piridilamino)-1-propiloxi]-5H- dibenzo[a,d]ciclohepten-10-acético, Acido (±)-10,11-dihidro-3-[2-[6-(etilamino)-2-piridil]-1- etoxi]-5H-dibenzo[a,d]ciclohepten-10- acético y Acido (±)-10,11-dihidro-3-[3-(4-metil-2- piridilamino)-1-propiloxi]-5H- dibenzo[a,d]ciclohepten-10-acético y sus sales farmacéuticamente aceptables. 1Un procedimiento para la preparación de un compuesto de fórmula (I): que consiste en reducir un compuesto de fórmula (II):
CO97075531A 1997-01-08 1997-12-30 Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin CO4920232A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3402697P 1997-01-08 1997-01-08

Publications (1)

Publication Number Publication Date
CO4920232A1 true CO4920232A1 (es) 2000-05-29

Family

ID=21873846

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97075531A CO4920232A1 (es) 1997-01-08 1997-12-30 Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin

Country Status (30)

Country Link
US (2) US6069158A (es)
EP (1) EP0977735B1 (es)
JP (1) JP2001508067A (es)
KR (1) KR20000069941A (es)
CN (1) CN1249745A (es)
AP (1) AP9901597A0 (es)
AR (1) AR010873A1 (es)
AT (1) ATE235467T1 (es)
AU (1) AU729641B2 (es)
BG (1) BG103548A (es)
BR (1) BR9806852A (es)
CA (1) CA2276738A1 (es)
CO (1) CO4920232A1 (es)
DE (1) DE69812602T2 (es)
DZ (1) DZ2395A1 (es)
EA (1) EA199900630A1 (es)
ES (1) ES2196534T3 (es)
HU (1) HUP0001945A3 (es)
ID (1) ID23168A (es)
IL (1) IL130760A0 (es)
MA (1) MA26462A1 (es)
NO (1) NO993350L (es)
NZ (1) NZ336560A (es)
OA (1) OA11076A (es)
PE (1) PE44799A1 (es)
PL (1) PL334499A1 (es)
SK (1) SK92799A3 (es)
TR (1) TR199901575T2 (es)
WO (1) WO1998030542A1 (es)
ZA (1) ZA9896B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011626A1 (en) * 1997-09-04 1999-03-11 Smithkline Beecham Corporation Integrin receptor antagonists
US6576643B2 (en) 1997-09-19 2003-06-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
PE122699A1 (es) * 1997-09-19 2000-02-12 Smithkline Beecham Corp Antagonistas de receptores de vitronectina
JP4064059B2 (ja) 1998-04-09 2008-03-19 明治製菓株式会社 インテグリンαＶβ３拮抗剤としてのアミノピペリジン誘導体
JP4240424B2 (ja) * 1998-10-23 2009-03-18 エルジー ディスプレイ カンパニー リミテッド エッチング剤及びこれを用いた電子機器用基板の製造方法
US6339083B1 (en) 1998-12-14 2002-01-15 Bayer Aktiengesellschaft Multiheterocyclic pharmAceuticals
AU747503B2 (en) 1999-02-03 2002-05-16 Merck & Co., Inc. Benzazepine derivatives as alpha-V integrin receptor antagonists
DE19916837A1 (de) * 1999-04-14 2000-10-19 Merck Patent Gmbh Dibenzoazulenderivate
EP1209152A4 (en) 1999-08-05 2003-03-12 Meiji Seika Kaisha OMEGA-AMINO-ALPHA-HYDROXY-CARBONIC ACID DERIVATIVES WITH AN INTEGRIN ALPHA V BETA ANTAGONISM
DE19936780A1 (de) 1999-08-09 2001-02-15 Basf Ag Neue Antagonisten von Integrinrezeptoren
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2004513953A (ja) * 2000-10-24 2004-05-13 メルク　エンド　カムパニー　インコーポレーテッド ジベンズオキサゼピンαＶインテグリン受容体アンタゴニスト
RU2316337C2 (ru) 2001-04-24 2008-02-10 Мерк Патент Гмбх КОМБИНИРОВАННАЯ ТЕРАПИЯ, ИСПОЛЬЗУЮЩАЯ АНТИАНГИОГЕННЫЕ СРЕДСТВА И TNF-α
KR101159061B1 (ko) 2001-10-22 2012-06-22 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
GB0215867D0 (en) * 2002-07-09 2002-08-14 Glaxosmithkline Spa Novel method and compounds
EP2394662B1 (en) * 2004-04-02 2018-03-21 The Regents of The University of California Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
AU2012216372B2 (en) * 2004-04-02 2015-01-22 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2006128689A2 (de) 2005-05-31 2006-12-07 Ralf Jochem Therapeutsche zusammensetzung zur vorbeugung und bekämpfung von knochenmetastasen
EP1945262A2 (en) * 2005-10-20 2008-07-23 The Scripps Research Institute Fc labeling for immunostaining and immunotargeting
ES2521679T3 (es) 2006-01-18 2014-11-13 Merck Patent Gmbh Terapia específica usando ligandos de integrinas para el tratamiento del cáncer
MX2009007597A (es) 2007-01-18 2009-07-22 Merck Patent Gmbh Terapia especifica y medicamento que utilizan ligandos de integrina para tratar el cancer.
WO2009082437A2 (en) 2007-12-21 2009-07-02 Ligand Pharmaceuticals Incorporated Selective androgen receptor modulators (sarms) and uses thereof
WO2010093706A2 (en) 2009-02-10 2010-08-19 The Scripps Research Institute Chemically programmed vaccination
EA201101651A1 (ru) 2009-05-25 2012-08-30 Мерк Патент Гмбх Непрерывное введение интегриновых лигандов для лечения рака
AU2010275367B2 (en) 2009-07-24 2015-09-03 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with avB5 integrin
CN106572997A (zh) 2014-05-30 2017-04-19 辉瑞公司 作为选择性雄激素受体调节剂的腈衍生物
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794424A (fr) * 1972-01-24 1973-07-23 Science Union & Cie Nouveaux dibenzocycloheptenes, leur procede d'obtention et leur application comme medicament
US3906032A (en) * 1972-11-10 1975-09-16 Squibb & Sons Inc Dihydroxy-tetrahydronaphthyoxyisobutyric acids and alkyl esters and salts thereof
IT1222986B (it) * 1987-10-23 1990-09-12 Texcontor Ets Derivati dell'efedrina esterificata aventi attivita' antiulcera prolungata nel tempo
US4994463A (en) * 1987-12-14 1991-02-19 Kyowa Hakko Kogyo Co., Ltd. Tricyclic thromboxane A2 antagonists
ATE238996T1 (de) * 1995-06-29 2003-05-15 Smithkline Beecham Corp Integrin-rezeptor-antagonisten
KR19990076877A (ko) * 1995-12-29 1999-10-25 스티븐 베네티아너 비트로넥틴 수용체 길항제
CA2297910A1 (en) * 1997-07-25 1999-02-04 Smithkline Beecham Corporation Vitronectin receptor antagonist
PE122699A1 (es) * 1997-09-19 2000-02-12 Smithkline Beecham Corp Antagonistas de receptores de vitronectina

Also Published As

Publication number Publication date
EP0977735A4 (en) 2000-04-05
JP2001508067A (ja) 2001-06-19
AR010873A1 (es) 2000-07-12
NO993350L (no) 1999-09-06
SK92799A3 (en) 1999-12-10
US6191304B1 (en) 2001-02-20
DE69812602D1 (de) 2003-04-30
ES2196534T3 (es) 2003-12-16
ID23168A (id) 2000-03-23
WO1998030542A1 (en) 1998-07-16
ZA9896B (en) 1998-10-14
HUP0001945A3 (en) 2001-12-28
BG103548A (en) 2000-11-30
DE69812602T2 (de) 2004-02-19
US6069158A (en) 2000-05-30
AU729641B2 (en) 2001-02-08
CA2276738A1 (en) 1998-07-16
MA26462A1 (fr) 2004-12-20
ATE235467T1 (de) 2003-04-15
BR9806852A (pt) 2001-08-07
CN1249745A (zh) 2000-04-05
AU5912798A (en) 1998-08-03
PL334499A1 (en) 2000-02-28
EP0977735A1 (en) 2000-02-09
HUP0001945A2 (hu) 2000-10-28
PE44799A1 (es) 1999-06-10
OA11076A (en) 2003-03-13
IL130760A0 (en) 2001-01-28
TR199901575T2 (xx) 1999-11-22
KR20000069941A (ko) 2000-11-25
NZ336560A (en) 2000-11-24
AP9901597A0 (en) 1999-09-30
EP0977735B1 (en) 2003-03-26
NO993350D0 (no) 1999-07-07
DZ2395A1 (fr) 2003-06-04
EA199900630A1 (ru) 2000-02-28

Similar Documents

Publication Publication Date Title
CO4920232A1 (es) Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin
EE9900535A (et) Fumaarhappe derivaatide kasutamine
DK0674642T3 (da) Pyrazolopyrimidiner som CRF-antagonister
MX9300014A (es) Nuevos derivados de 1,2,4-triaminobenceno y procedimiento para su elaboracion.
TR199801642T2 (xx) Tedavide faydal� olan karbamik asitlerin azabisiklik esterleri.
AR038430A2 (es) Derivados de parahercuamida b
ES2143132T3 (es) Monohidratos de derivado de acido aminobenceno-sulfonico y su metodo de preparacion.
ES2275313T3 (es) Derivados de amida como promotores de la liberacion de la hormona del crecimiento.
CA2247520A1 (fr) Composition pharmaceutique a base de rheine ou de diacerheine a biodisponibilite amelioree
SV2002000137A (es) Productos farmaceuticos beta-carbolina ref n. 29342/36539 el
DE3778770D1 (de) Neue diphenylpropylamin-derivate, ihre herstellung sowie ihre pharmazeutische verwendung.
ES2058173T3 (es) Dioxialquilenaril-dihidropiridinas, productos intermedios para su fabricacion, procedimientos para su fabricacion y su utilizacion.
MX9300779A (es) 3-(1h-tetrazol-5-y1)-4h-pyrido[1,2-a]pirimidina-4-onas composiciones farmaceuticas que las contienen y su preparacion de las mismas
ES2145360T3 (es) Sales cristalinas y estables de acido tetrahidrofolico.
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
ES2043943T3 (es) Procedimiento para la preparacion de compuestos con actividad analgesica central.
YU37001A (sh) Kombinacija lekova analgetika
BR0013750A (pt) Intermediários para a produção de derivados de ácido naftiridina-3-carboxìlico
ZA885367B (en) Benzimidazole derivatives,their preparation and their application in therapeutics
ES2031816T3 (es) Derivados triciclicos de la piridona.
PT98509A (pt) Metodo para o abaixamento dos niveis de acido urico no sangue com derivados de acido acetico oxoftalazinilo
PT98186A (pt) Processo para a preparacao de purinil- e de pirimidinil-tetra-hidrofuranos e de composicoes farmaceuticas que os contem
DE3675291D1 (de) 1-alkyl-ergolinyl-thioharnstoffderivate.
BR9810031A (pt) Derivados de ácido pirrolidina carboxìlico como antagonistas á endotelina